EP3117823A1 — Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
Assigned to Quimica Sintetica SA · Expires 2017-01-18 · 9y expired
What this patent protects
Are described an amorphous solid dispersion comprising a 1:1 stoichiometric mixture of the sodium salts of Valsartan and Sacubitril useful in the treatment of essential hypertension and/or cardiac failure, possibly in the form of a pharmaceutical composition comprising said amorp…
USPTO Abstract
Are described an amorphous solid dispersion comprising a 1:1 stoichiometric mixture of the sodium salts of Valsartan and Sacubitril useful in the treatment of essential hypertension and/or cardiac failure, possibly in the form of a pharmaceutical composition comprising said amorphous solid dispersion and at least one pharmaceutically acceptable carrier, as well as methods for the preparation of the amorphous solid dispersion.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.